Λεπτομέρειες βιβλιογραφικής εγγραφής
| Τίτλος: |
Target, silence, replace: a review on RNA-based drugs in modern medicine. |
| Συγγραφείς: |
Mundlia, Poonam, Singh, Suraj Pratap, Pothal, Pritiman, Thakur, Tanya, Kathuria, Reema, Maurya, Sudhanshu, Sharma, Akanksha, Goel, Honey, Pandey, Ankur, Ranawat, Pavitra, Singh, Gurpal, Barnwal, Ravi Pratap |
| Πηγή: |
Frontiers in Cell & Developmental Biology; 2026, p1-35, 35p |
| Θεματικοί όροι: |
Small interfering RNA, mRNA vaccines, RNA-binding proteins, Oligonucleotides, CRISPRs, RNA interference, Cancer treatment, Antisense RNA |
| Περίληψη: |
RNA therapies have evolved into a revolutionary approach in contemporary medicine for treating various diseases by directly targeting RNA molecules engaged in disease pathogenesis. These therapeutic agents regulate biological processes through diverse mechanisms, including modulation of RNA function and gene expression. Medical applications of RNA are greatly enhanced by its structure, adaptability, and capacity for targeted binding. Among these traits is its ability to bind to certain molecules unique to those chemicals. RNA-based treatments have emerged from advancements in the production, modification, and cellular transport of RNA molecules. Several RNA drugs have been approved whereas some are under trial for few diseases. RNA therapeutics can function at the level of RNAs, DNAs and proteins. The evolution of mRNA vaccines during the COVID-19 epidemic emphasizes the exciting potential of RNA therapies in the treatment of diseases. This article provides a comprehensive overview of the several forms of RNA therapies, including small-interfering RNA (siRNA), messenger RNA (mRNA), and antisense-oligonucleotides (ASOs), together with information on their action mechanisms and delivery strategies that improve cellular absorption and shield RNA molecules from degradation. Further, CRISPR-based editing of the genome can be employed for modification of target RNA sequences for various disorders. Development of RNA aptamers have also been identified as pivotal RNA-therapeutic candidate. Additionally, we have explained mechanistic details and examples of drugs approved for RNA therapy. Emphasizing their potential to enhance patient outcomes and fulfil unmet medical requirements, we also highlight the clinical development of RNA therapies in treating cancer and other infectious diseases. [ABSTRACT FROM AUTHOR] |
|
Copyright of Frontiers in Cell & Developmental Biology is the property of Frontiers Media S.A. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Βάση Δεδομένων: |
Complementary Index |